COVD-23. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC

MLA

Louis B. Nabors, et al. “Covd-23. Planned-Use Glucarpidase for Outpatient High Dose Methotrexate (Hd-Mtx) Administration in Patients with Cns Lymphoma (Cnsl) during the Covid-19 Pandemic.” Neuro-Oncology, vol. 22, Nov. 2020, pp. ii25-ii26. EBSCOhost, https://doi.org/10.1093/neuonc/noaa215.105.

APA

Louis B. Nabors, Alexis Bozza, Dean Carlow, Mina Lobbous, Lauren Schaff, & Christian Grommes. (2020). Covd-23. Planned-Use Glucarpidase for Outpatient High Dose Methotrexate (Hd-Mtx) Administration in Patients with Cns Lymphoma (Cnsl) during the Covid-19 Pandemic. Neuro-Oncology, 22, ii25-ii26. https://doi.org/10.1093/neuonc/noaa215.105

Chicago

Louis B. Nabors, Alexis Bozza, Dean Carlow, Mina Lobbous, Lauren Schaff, and Christian Grommes. 2020. “Covd-23. Planned-Use Glucarpidase for Outpatient High Dose Methotrexate (Hd-Mtx) Administration in Patients with Cns Lymphoma (Cnsl) during the Covid-19 Pandemic.” Neuro-Oncology 22 (November): ii25-ii26. doi:10.1093/neuonc/noaa215.105.